Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by BearDownAZon Feb 11, 2020 10:51am

188 Views

Post# 30673762

PACE-CME Videos from 2019 ESC, AHA and ERA-EDTA

PACE-CME videos from ESC 2019 symposium and of AHA 2019 BETonMACE results are now posted. Note, you may need to register for a free account to access some of these. I've also linked to the ERA-EDTA symposium presentations too.

https://pace-cme.org/epigenetics-in-cvd/

Effect of BET inhibition on CV outcomes in ACS and diabetes patients, presented by Dr. Kausik Ray

https://pace-cme.org/2019/12/09/effect-of-bet-inhibition-on-cv-outcomes-in-acs-and-diabetes-patients/

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition, presented by Dr. Kausik Ray

https://pace-cme.org/2019/10/02/clinical-update-on-bet-inhibition-the-patient-profile-that-may-benefit-from-bet-inhibition/

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?, presented by Dr. Wouter Jukema

https://pace-cme.org/2019/09/30/bet-inhibition-an-epigenetic-pathway-how-could-bet-inhibition-modulate-atherothrombotic-risk/

Challenges in targeting residual risk in diabetic patients, post ACS, presented by Dr. Peter Libby

https://pace-cme.org/2019/09/25/challenges-in-targeting-residual-risk-in-diabetic-patients-post-acs/

Also, if you missed the ER-EDTA symposium presentations, they are here to:

https://pace-cme.org/epigenetics-in-cvd/

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?, presented by Dr. Marta Ruiz-Ortega